Metraipolis › archive › dc_f5e39b140d0d

Late-phase strategies to overcome limitations of PD-1/PD-L1 therapy: a clinical development trajectory through 2030 — Europe PMC PMID:42577818

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42577818
DOI
10.3389/fonc.2026.1875861
License (as archived)
solo-consultazione
Archived
2026-10-18T03:54:04.085Z
SHA-256 of the archived text
1b500c41cabeaa66e394b4eba55d0a96d3ae18563528e8863fb30f83a74c937a
Stable URL of this page
https://metraipolis.com/documento/dc_f5e39b140d0d

How to cite

Late-phase strategies to overcome limitations of PD-1/PD-L1 therapy: a clinical development trajectory through 2030 — Europe PMC PMID:42577818 — Europe PMC (en), https://europepmc.org/article/MED/42577818 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f5e39b140d0d (Metraipolis archive dc_f5e39b140d0d, sha256 1b500c41cabeaa66e394b4eba55d0a96d3ae18563528e8863fb30f83a74c937a)
BibTeX
@misc{dcf5e39b140d0d,
  title = {Late-phase strategies to overcome limitations of PD-1/PD-L1 therapy: a clinical development trajectory through 2030 — Europe PMC PMID:42577818},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42577818},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f5e39b140d0d; sha256 1b500c41cabeaa66e394b4eba55d0a96d3ae18563528e8863fb30f83a74c937a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42577818. Agents can read the archived copy with the MCP tool read_document.